Precipio (NASDAQ:PRPO) Downgraded by Wall Street Zen to Hold

Wall Street Zen lowered shares of Precipio (NASDAQ:PRPO) from a buy rating to a hold rating in a report released on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Precipio in a research note on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Precipio Price Performance

Shares of Precipio stock opened at $26.04 on Friday. The firm has a fifty day simple moving average of $27.84 and a 200-day simple moving average of $24.85. The company has a current ratio of 1.61, a quick ratio of 1.36 and a debt-to-equity ratio of 0.05. Precipio has a 1-year low of $7.31 and a 1-year high of $33.63. The stock has a market capitalization of $46.35 million, a price-to-earnings ratio of -55.40 and a beta of 1.38.

Precipio (NASDAQ:PRPO) last issued its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.81) earnings per share for the quarter. Precipio had a negative return on equity of 6.81% and a negative net margin of 3.57%.The firm had revenue of $6.71 million during the quarter.

Hedge Funds Weigh In On Precipio

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC increased its position in Precipio by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 789 shares during the period. Renaissance Technologies LLC increased its position in Precipio by 10.7% during the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after acquiring an additional 1,400 shares during the period. Susquehanna International Group LLP bought a new position in Precipio during the third quarter worth $194,000. Evernest Financial Advisors LLC bought a new position in Precipio during the third quarter worth $374,000. Finally, Topline Capital Management LLC bought a new position in Precipio during the third quarter worth $1,158,000. Institutional investors own 10.45% of the company’s stock.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.